Table 1 Characteristics of pharmacotherapy criteria for older adults
AGS Beer’s criteria 2015 1) | STOPP/START v2 2015 2) | JGS STOPP-J 2015 3) | |
|---|---|---|---|
Latest version Developed | AGS | Study group at University College Cork | JGS |
Original version (year, developer) | 1991, Dr. Beers | 2008, Study group at University College Cork | 2005, JGS |
Target population | United States; 65 and older; Ambulatory, acute, and institutionalized settings | Europe-wide prescribing practices;65 and older; in most clinical settings | Japan; 75 and older; 74 and younger with frailty; 65 and older in need of nursing care; chronic treatment |
Therapeutic category / drug | 26 potentially inappropriate medication (PIM) 12 PIM due to drug-disease/ drug-syndrome interactions 5 PIM to be used with caution 10 PIM non-anti-infective drug-drug interactions that should be avoided in older adults | 80 criteria in STOPP 34 criteria in START | 29 groups for drugs to be prescribed with special caution 8 groups for drugs to consider starting |
Remarks | Supplement information: “Quality of evidence” and “Strength of Recommendation” | For adverse drug events prevention and cost reduction | Supplement information: “Quality of evidence” and “Strength of Recommendation” |